|
Health Affairs, 29, no. 2 (2010):
297-303
(Published online 14 January 2010)
doi: 10.1377/hlthaff.2009.0155
© 2010 by Project HOPE
|
|
 |
|
|
|
The Economic Burden Of Diabetes
Timothy M. Dall1,*,
Yiduo Zhang2,
Yaozhu J. Chen3,
William W. Quick4,
Wenya G. Yang5 and
Jeanene Fogli6
1 Timothy M. Dall (tim.dall{at}lewin.com) is managing director, applied economics, at the Lewin Group in Falls Church, Virginia.
2 Yiduo Zhang is a senior associate at the Lewin Group.
3 Yaozhu J. Chen is a senior associate at the Lewin Group.
4 William W. Quick is executive medical director, Endocrinology and Metabolic Disease, Medical and Scientific Affairs, at i3 Research in Basking Ridge, New Jersey.
5 Wenya G. Yang is a senior associate at the Lewin Group.
6 Jeanene Fogli is director, Endocrinology, Metabolic Disease, and Cardiology, Medical and Scientific Affairs, at i3 Research in Boston, Massachusetts.
New research provides revised comprehensive estimates that suggest that the U.S. national economic burden of pre-diabetes and diabetes reached $218 billion in 2007. This estimate includes $153 billion in higher medical costs and $65 billion in reduced productivity. The average annual cost per case is $2,864 for undiagnosed diabetes, $9,975 for diagnosed diabetes ($9,677 for type 2 and $14,856 for type 1), and $443 for pre-diabetes (medical costs only). For each American, regardless of diabetes status, this burden represents a cost of approximately $700 annually. These results underscore the urgency of better understanding how prevention and treatment strategies may or may not help reduce costs.
Key Words: Health Care Costs • Economic Burden • Diabetes
       What's this?
|
